cemiplimab sold brand name libtayo monoclonal antibody medication treatment squamous cell skin cemiplimab belongs class drugs binds programmed death blocking common side effects include fatigue rash diarrhea musculoskeletal pain september approved us food drug administration fda treating people metastatic cutaneous squamous cell carcinoma cscc locally advanced cscc candidates curative surgery curative approved medical use european union june approved medical use australia july cemiplimab first fda approval medication specifically advanced cutaneous squamous cell carcinoma cemiplimab indicated treatment patients metastatic cutaneous squamous cell carcinoma cscc locally advanced cscc candidates curative surgery curative cemiplimab associated side effects related activity immune system serious although side effects go away appropriate treatment stopping common immunerelated effects may affect people hypothyroidism underactive thyroid gland tiredness weight gain skin hair changes pneumonitis inflammation lungs causing shortness breath cough skin reactions hyperthyroidism overactive thyroid gland cause hyperactivity sweating weight loss thirst hepatitis inflammation severe reactions including syndrome toxic epidermal necrolysis lifethreatening reactions flulike symptoms painful rash affecting skin mouth eyes genitals reported cemiplimab cause harm developing fetus women advised potential risk fetus use effective cemiplimab targets cellular pathway known protein found bodys immune cells cancer cells acts checkpoint safety efficacy cemiplimab studied two open label clinical total participants metastatic disease locally advanced disease included efficacy studys primary endpoint objective response rate percentage participants experienced partial shrinkage complete disappearance tumors results showed percent participants treated cemiplimab tumors shrink majority participants ongoing responses time data us food drug administration fda granted application cemiplimab breakthrough therapy priority review fda granted approval cemiplimabrwlc regeneron pharmaceuticals november fda approved cemiplimab combination platinumbased chemotherapy adults advanced nonsmall cell lung cancer nsclc egfr alk cemiplimab investigated treatment cemiplimab investigated treatment lung cemiplimab phase clinical trials advanced cervical based findings phase empowercervical trial european medicines agency committee medicinal products human use adopted positive opinion libtayo monotherapy treatment adult patients recurrent metastatic cervical cancer disease progression platinumbased cemiplimab phase clinical trials treatment cutaneous squamous cell immune activation dostarlimab ibalizumab httpsenwikipediaorgwikicemiplimab